Website intended for a NZ health professional readership
This article provides an update on respiratory syncytial virus vaccines and monoclonal antibodies
1. Prasad N, Newbern EC, Trenholme AA, et al. The health and economic burden of respiratory syncytial virus associated hospitalizations in adults. PLoS One 2020;15(6):e0234235.
2. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther 2009;14(2):75–85.
3. Shi T, Vennard S, Mahdy S, Nair H. Risk factors for poor outcome or death in young children with respiratory syncytial virus-associated acute lower respiratory tract infection: A systematic review and meta-analysis. J Infect Dis 2022;226(Suppl 1):S10–16.
4. Brenes-Chacon H, Garcia-Maurino C, Moore-Clingenpeel M, et al. Age-dependent interactions among clinical characteristics, viral loads and disease severity in young children with respiratory syncytial virus infection. Pediatr Infect Dis J 2021;40(2):116–22.
5. Prasad N, Newbern EC, Trenholme AA, et al. Respiratory syncytial virus hospitalisations among young children: a data linkage study. Epidemiol Infect 2019;147:e246.
6. Ison MG, Papi A, Athan E, et al. Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024; 22 January online.
7. Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023;388(16):1465–77.
8. Pfizer. Pfizer announces positive top-line data for full season two efficacy of Abrysvo® for RSV in older adults [press release]. 29 February 2024.
9. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023;388(16):1451–64.
11. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022;386(9):837–46.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
